Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;16(6):693-702.
doi: 10.1007/s11914-018-0486-0.

CKD-MBD: from the Pathogenesis to the Identification and Development of Potential Novel Therapeutic Targets

Rosilene Motta Elias  1   2 , Maria Aparecida Dalboni  1 , Ana Carolina E Coelho  3 , Rosa M A Moysés  4   5
Affiliations
Review

CKD-MBD: from the Pathogenesis to the Identification and Development of Potential Novel Therapeutic Targets

Rosilene Motta Elias et al. Curr Osteoporos Rep. 2018 Dec.

Abstract

Purpose of review: Although we have seen tremendous advances in the comprehension of CKD-MBD pathophysiology during the last few years, this was not accompanied by a significant change in mortality rate and quality of life. This review will address the traditional and updated pathophysiology of CKD-MBD along with the therapeutic limitations that affect CKD-MBD and proposed alternative treatment targets.

Recent findings: An innovative concept brings the osteocyte to the center of CKD-MBD pathophysiology, in contrast to the traditional view of the skeleton as a target organ for disturbances in calcium, phosphate, parathyroid hormone, and vitamin D. Osteocytes, through the synthesis of FGF-23, sclerostin, among others, are able to interact with other organs, making bone an endocrine organ. Thus, osteocyte dysregulation might be an early event during the course of CKD. This review will revisit general concepts on the pathophysiology of CKD-MBD and discuss new perspectives for its treatment.

Keywords: CKD-MBD; FGF-23; Osteocyte; Sclerostin; Secondary hyperparathyroidism.

PubMed Disclaimer

References

    1. Hypertension. 2011 Nov;58(5):811-7 - PubMed
    1. J Immunol. 2005 Dec 15;175(12):8287-95 - PubMed
    1. J Am Soc Nephrol. 2007 Sep;18(9):2509-16 - PubMed
    1. Sleep. 2013 Oct 01;36(10):1509-15 - PubMed
    1. J Bone Miner Res. 2012 Aug;27(8):1757-72 - PubMed

MeSH terms

LinkOut - more resources